ABOUT US
Company Overview
The GrayMatters team is excited to bring evidence-based innovations to psychiatry clinics and empower both patients and providers.
GMH is actively marketing Prism for PTSD, an FDA-cleared device being used today to treat patients with PTSD in a growing list of psychiatry clinics across the US. An expert team in the US is leading commercial growth, market access, medical strategy and training programs.
GMH is the first company to develop a PTSD treatment based on a proprietary amygdala-based digital biomarker. While medical biomarkers measure tissue to assess disease, the EFP (EEG-fMRI-Pattern) biomarker measures brain activity associated with mental health disorders.
This is the world’s first biomarker that harnesses advanced statistical models to register fMRI amygdala data to readily accessible EEG. This innovation brings the power of evidence-based, precision neurofeedback to any psychiatry clinic treating PTSD patients.
The company's FDA-cleared device, Prism, uses a computer simulation and EEG headset to help patients learn to regulate brain activity associated with PTSD symptoms. Prism is to be used under the direction of a healthcare professional as an adjunct to standard-of-care therapy. Prism for PTSD was a Gold winner of the 2024 Edison Awards, receiving recognition as a groundbreaking category-changer to improve lives for the better and the 2021 Nature Spinoff Prize, sponsored by 'Nature' the world's leading scientific research journal and the Merck Group.
Founded in 2018 by Oded Kraft, Rani Cohen and Shai Attia, GMH is on a mission to connect mental health disorders to their underlying brain mechanisms to improve patient care and outcomes. The company name is a play on words highlighting the importance of the gray matter of the brain as well as the significance of the knowledge and experience that comes with the gray hairs of age.
The company was recognized in 2024 as a Most Innovative Company by Fast Magazine and in 2023, received the Prix Galien USA Best Startup Award. The company’s patented core technology was invented by Professor Talma Hendler, MD, PhD and her team at Tel Aviv University, with further development by GMH’s talented team of scientists, engineers, clinical and product experts.
GMH is collaborating with key medical institutions to explore EFP biomarkers for treating mental health disorders beyond PTSD.
OUR TEAM
Prof. Talma Hendler, MD, PhD
Inventor, SAB Chairperson,
Chief Medical Scientist
Oded Kraft
CEO, President
Co-founder
Rani Cohen
Executive Chairman BOD,
Co-founder
Shai Attia
VP R&D , Co-founder
Adar Shani
VP Clinical,
Regulatory & Quality Affairs
Dr. Aron Tendler
Chief Medical Officer
Kirk Thelander
Chief Commercial Officer
Pam Schwartz
VP Marketing
AWARDS
Best Startup Award 2023
OUR PARTNERS
